Sign up for free ground shipping on all website orders, no minimum required, and get exclusive coupons!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 154361-50-9 | Product Number: C2878
Capecitabine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 5'-Deoxy-5-fluoro-N4-[(pentyloxy)carbonyl]cytidine
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 1G |
$118.00
|
Contact Us | 1 | 2 |
|
| 5G |
$407.00
|
Contact Us | Contact Us | ≥100 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | C2878 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__5H__2__2FN__3O__6 = 359.35 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 154361-50-9 |
| Reaxys Registry Number | 8583270 |
| PubChem Substance ID | 253661933 |
| Merck Index (14) | 1754 |
| MDL Number | MFCD00930626 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | +96.0 to +100.0 deg(C=1, MeOH) |
Properties (reference)
| Melting Point | 123 °C(dec.) |
| Specific Rotation | 98° (C=1,MeOH) |
| Solubility in water | Slightly soluble |
| Degree of solubility in water | 26 g/l 20 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H360 : May damage fertility or the unborn child. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P302 + P352 : IF ON SKIN: Wash with plenty of soap and water. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P362 : Take off contaminated clothing and wash before reuse. P405 : Store locked up. |
Related Laws:
| RTECS# | HA3852500 |
Transport Information:
| HS Number | 2934.99.4400 |
Application
Capecitabine: A Prodrug of 5-fluorouracil (5-FU) [F0151] for Selective Delivery to Tumor
Capecitabine is a prodrug of antitumor antimetabolite, metabolized to the active form 5-fluorouracil (5-FU) [F0151] by three enzymes located in the liver and in tumors. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine [D4342] and 5'-deoxy-5-fluorouridine (doxifluridine) [D3579], to form 5-FU. Capecitabine and its intermediary metabolites are not cytotoxic by themselves. The final step (doxifluridine to 5-FU) requires thymidine phosphorylase (dThdPase) that is significantly more active in tumor than normal tissue. This tumor-selective delivery of 5-FU ensured greater efficacy and a more favorable safety profile than with other fluoropyrimidines. For your reference, [D5787] is a synthetic precursor of capecitabine. (The product is for research purpose only.)
References
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
- Capecitabine: preclinical pharmacology studies (a review)
- Clinical pharmacokinetics of capecitabine (a review)
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Capecitabine: an overview of the side effects and their management (a review)
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.